The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Retrospective analysis of the safety and efficacy of vandetanib as systemic treatment for patients with advanced and progressive medullary thyroid cancer (MTC).
Jaume Capdevila
No relevant relationships to disclose
Javier Martinez-Trufero
No relevant relationships to disclose
Elsa Dalmau
No relevant relationships to disclose
Cristina Alvarez-Escola
No relevant relationships to disclose
Miguel Beltran
No relevant relationships to disclose
Manuel Duran
No relevant relationships to disclose
Isabel Gallegos
No relevant relationships to disclose
Jose Luis Manzano
No relevant relationships to disclose
Ricard Mesia
No relevant relationships to disclose
Isabel Pajares
No relevant relationships to disclose
Jose Fuentes Pradera
No relevant relationships to disclose
Juan J. Grau
No relevant relationships to disclose
Òscar Reig
No relevant relationships to disclose
Jose Manuel Trigo
No relevant relationships to disclose
Enrique Grande
No relevant relationships to disclose